Skip to content

the effect of sertraline in dialysis associated hypotention

the effect of sertraline in dialysis associated hypotention

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201112033043N3
Enrollment
20
Registered
2012-01-06
Start date
2011-10-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dialysis associated hypotention. Kidney dialysis?Hypotension

Interventions

Intervention 1: treatment group:administration tablet of sertraline 50-100mg once daily for 8 weeks. Intervention 2: control group:administration placebo of sertralin50-100mg once daily for 8 weeks.
Treatment - Drugs
treatment group:administration tablet of sertraline 50-100mg once daily for 8 weeks
control group:administration placebo of sertralin50-100mg once daily for 8 weeks

Sponsors

Tehran University of Medical Science and Health Services
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: inclusion:patient suffer from dialysis associated hypotention exclusion:systolic dysfunction,patients who can not tolerate sertraline's adverse effect,refusal to participate in the study,usage of midodrin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Hypotention. Timepoint: 4weeks before intervention,during intervention,4weeks after intervention. Method of measurement: mmhg with use of digital barometer.

Secondary

MeasureTime frame
Complications of hypotention such as cramp,dizziness,headache,neusea and vomiting,. Timepoint: 4weeks before intervention,during intervention,4weeks after intervention. Method of measurement: observation.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026